XML 40 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 5,746,184 $ 6,875,273
Investment in debt securities - available for sale, at fair value 9,887,455 7,985,886
Accrued interest receivable on investment securities 22,713 21,369
Receivable on sale of net operating losses 1,819,324
Advances and deposits on clinical programs and other current assets 1,401,024 1,352,670
Total current assets 18,876,700 16,235,198
Property and equipment (at cost, less accumulated depreciation of $3,135,681 and $3,096,681, respectively) 374,598 405,363
Other assets:    
Deferred tax asset 1,819,324
In-process research and development, net 15,736,491 15,736,491
Goodwill 1,976,101 1,976,101
Operating lease right-of-use assets, net 1,339,140 1,431,640
Other intangible assets, net 284,147 340,976
Deposits and other assets 349,447 333,274
Total other assets 19,685,326 21,637,806
Total assets 38,936,624 38,278,367
Current liabilities:    
Accounts payable - trade 2,856,378 2,862,949
Other accrued liabilities 1,399,070 2,303,547
Notes payable - current portion, net of deferred financing costs 2,276,005 1,840,228
Operating lease liability - current portion 398,731 387,733
Deferred revenue - current portion 500,000 500,000
Total current liabilities 7,430,184 7,894,457
Earn-out milestone liability 5,758,983 5,717,709
Note payable, net of deferred financing costs 7,623,738 7,963,449
Operating lease liability - non-current portion 1,040,183 1,143,717
Deferred revenue - non-current portion 875,000 1,000,000
Total liabilities 22,728,088 23,719,332
Commitments and contingencies
Stockholders' equity:    
Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at March 31, 2020 and December 31, 2019)
Common stock - $0.01 par value (112,500,000 shares authorized; 29,257,435 and 23,256,152 shares issued at March 31, 2020 and December 31, 2019, respectively, and 29,257,101 and 23,255,818 shares outstanding at March 31, 2020 and December 31, 2019, respectively) 292,574 232,562
Additional paid-in capital 311,570,995 304,885,663
Accumulated other comprehensive gain 3,813 42,778
Accumulated deficit (295,573,658) (290,516,780)
Total stockholders' equity before treasury stock 16,293,724 14,644,223
Treasury stock, at cost (334 shares at March 31, 2020 and December 31, 2019) (85,188) (85,188)
Total stockholders' equity 16,208,536 14,559,035
Total liabilities and stockholders' equity $ 38,936,624 $ 38,278,367